A. Prasse (Hannover, Germany), M. Bonifazi (Ancona (AN), Italy)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Impact and outcome of COVID-19 on SSc-ILD
A. Hoffmann-Vold (Oslo, Norway), C. Brunborg (Oslo, Norway), F. Tirelli (Zurich, Switzerland), P. Carreira (Madrid, Spain), N. Del Papa (Milan, Italy), A. Mekinian (Paris, France), M. Vonk (Nijmegen, Netherlands), A. Giollo (Verona, Italy), G. De Luca (Milan, Italy), M. De Santis (Milan, Italy), C. Campochiaro (Milan, Italy), C. Mihai (Zurich, Switzerland), P. Airo (Brescia, Italy), M. Lazzaroni (Brescia, Italy), E. Zanatta (Padova, Italy), R. Foti (Catania, Italy), Y. Allanore (Paris, France), D. Furst ( |   |
Decisional algorithm in the differential diagnosis of lung outcomes from COVID-19.
s. vernocchi (Abbiategrasso, Italy), T. Serini (Chiasso, Switzerland), A. Aceranti (Milano, Italy), O. Grassi (Cuggiono, Italy), L. Tomaello (Abbiategrasso, Italy), E. Pagliaro (Milano, Italy), N. Mumoli (Magenta, Italy)
| |
Homemonitoring after hospital admission for COVID-19:the HOMECOMIN' study
G. Nakshbandi (Rotterdam, Netherlands), C. Moor (Rotterdam, Netherlands), E. Nossent (Amsterdam, Netherlands), J. Geelhoed (Leiden, Netherlands), B. Boerrigter (Amsterdam, Netherlands), M. Hellemons (Rotterdam, Netherlands), S. Huijts (Rotterdam, Netherlands), S. Nijman (Amsterdam, Netherlands), H. Santema (Leiden, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands)
| |
Improvement in SARS-CoV2 lung interstitial injuries with systemic corticosteroid treatment
P. Copil (Bucharest, Romania), C. Toma (Bucharest, Romania), S. Dumitrache-Rujinski (Bucharest, Romania), T. Constantinescu (Bucharest, Romania), I. Belaconi (Bucharest, Romania), C. Ene (Bucharest, Romania), I. Ruseva (Bucharest, Romania), C. Iordache (Bucharest, Romania), E. Athir (Bucharest, Romania), R. Nemes (Bucharest, Romania)
| |
Pulmonary sequelae in patients with COVID-19: results after 3 months of follow-up
A. Stainer (Monza, Italy), P. Faverio (Monza, Italy), S. Busnelli (Monza, Italy), F. Luppi (Monza, Italy), A. Monzani (Monza, Italy), F. Ammatuna (Monza, Italy), F. Montanelli (Monza, Italy), M. Catalano (Monza, Italy), L. Parachini (Monza, Italy), S. Zucchetti (Garbagnate Milanese, Italy), A. Pesci (Monza, Italy)
| |
Seasonal epidemiology and clinical manifestations of interstitial lung diseases (ILD) as an important criterion for differential diagnosis viral pneumonia with pulmonary arterial hypertention (PAH) associated with severe COVID-19.
O. Yakovenko (Lutsk, Ukraine), T. Yakovenko (Lutsk, Ukraine), O. Liuta (Lutsk, Ukraine)
| |
Management of patients with ARDS secondary to Covid-19 who develop fibrotic changes in the Intensive Care Unit
G. Bermudo Peloche (Barcelona, Spain), M. Molina (Barcelona, Spain), V. Vicens (Barcelona, Spain), M. Hernández (Barcelona, Spain), G. Suárez (Barcelona, Spain), P. Trias (Barcelona, Spain), J. Bordas (Barcelona, Spain), S. Santos (Barcelona, Spain), S. Bolivar (Barcelona, Spain), B. Del Rio (Barcelona, Spain), J. Sabater (Barcelona, Spain), X. Perez (Barcelona, Spain), R. Jodar (Barcelona, Spain), M. Fuset (Barcelona, Spain)
| |
Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON
W. Wuyts (Leuven, Belgium), F. Bonella (Essen, Germany), N. Chaudhuri (Manchester, United Kingdom), F. Varone (Roma, Italy), D. Antin-Ozerkis (New Haven, CT, United States of America), H. Mueller (Biberach, Germany), C. Coeck (Brussels, Belgium), K. Rohr (Ingelheim am Rhein, Germany), V. Cottin (Lyon, France)
| |
Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: pooled data from four trials
C. Valenzuela (Madrid, Spain), S. Assassi (Houston, Texas, United States of America), F. Bonella (Essen, Germany), T. Maher (Los Angeles, California, United States of America), L. Loaiza (Ingelheim am Rhein, Germany), I. Tschoepe (Bietigheim-Bissingen, Germany), L. Orsatti (Ingelheim am Rhein, Germany), M. Kolb (Hamilton, Ontario, Canada)
| |
Characteristics of Connective Tissue Diseases Associated Interstitial Lung Diseases - A Single Centre Study in Sri Lanka
P. Jayasinghe (COLOMBO, Sri Lanka), N. Wickramasinghe (COLOMBO, Sri Lanka), P. Krishnakumar (COLOMBO, Sri Lanka), A. Sadikeen (COLOMBO, Sri Lanka), A. Fernando (COLOMBO, Sri Lanka)
| |
Interstitial lung diseases frequency in a regional reference center in Brazil
A. Medeiros De Neto (João Pessoa (PB), Brazil), M. Pereira Morais (João Pessoa (PB), Brazil), K. Dantas Saraiva (João Pessoa (PB), Brazil), M. Oliveira (João Pessoa (PB), Brazil), J. Parente Vieira (João Pessoa (PB), Brazil), A. Souza Braz (João Pessoa (PB), Brazil), F. Silva Queiroz (João Pessoa (PB), Brazil), A. Rolim Paz (João Pessoa (PB), Brazil), P. Abrantes Sarmento (João Pessoa (PB), Brazil), F. Barbosa Queiroga (João Pessoa (PB), Brazil), D. Pires Pessoa (João Pessoa (PB), Brazil)
| |
Incidence, prevalence and mortality of rheumatoid arthritis-associated interstitial lung disease : a retrospective study
A. Denis (Liège, Belgium), M. Henket (Liège, Belgium), F. Gester (Liège, Belgium), M. Thys (Liège, Belgium), M. Ernst (Liège, Belgium), N. Maes (Liège, Belgium), L. Giltay (Liège, Belgium), A. Frix (Liège, Belgium), Q. Maloir (Liège, Belgium), C. Desir (Liège, Belgium), P. Meunier (Liège, Belgium), R. Louis (Liège, Belgium), J. Guiot (Liège, Belgium)
| |
Pneumocystis jiroveci Pneumonia prophylaxis in patients treated with mycophenolate mofetil for interstitial lung disease
P. Ireland (Newcastle Upon Tyne, United Kingdom), L. Langlands (Newcastle Upon Tyne, United Kingdom), C. Donaldson (Newcastle Upon Tyne, United Kingdom), A. Simpson (Newcastle Upon Tyne, United Kingdom), I. Forrest (Newcastle Upon Tyne, United Kingdom), S. Wiscombe (Newcastle Upon Tyne, United Kingdom), W. Funston (Newcastle Upon Tyne, United Kingdom)
| |
Pleural plaque volume correlation to lung function and artificial intelligence-driven pleural plaque quantification
K. Groot Lipman (Amsterdam, Netherlands), T. Boellaard (Amsterdam, Netherlands), C. De Gooijer (Amsterdam, Netherlands), N. Bogveradze (Amsterdam, Netherlands), . Hong (Amsterdam, Netherlands), F. Landolfi (Amsterdam, Netherlands), F. Castagnoli (Amsterdam, Netherlands), L. Castro Cavallo (Amsterdam, Netherlands), N. Lebedyeva (Amsterdam, Netherlands), F. Van Der Heijden (Enschede, Netherlands), R. Beets-Tan (Amsterdam, Netherlands), Z. Bodalal (Amsterdam, Netherlands), S. Burgers (Amsterdam, Netherlands), S. Trebeschi (Amsterdam, Netherlands)
| |